focus -WSS

focus

author：fashion 2025-09-29 11:32:31 Page View：224

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What we owe ALS patients — and why one company fell short
Next article： Moonlake's readout produced a cash windfall. Risks remain

focus

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

1:21Thebeachisclosed.Thesignreads"Notice:thisbeachareamaynotbesuitableforswimmingduetohighlevelsofba

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

The stability of $0 premiums in Medicare Advantage

PabloMartinezMonsivais/APYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingt